Taken together, in combination with its underlying clinical implications and well-characterized tumor biological effects, our current work identified FOSB as a novel and promising prognostic biomarker for NSCLC with a given genetic background of TP53. Although rarely, to our knowledge, in addition to FOSB, there are other molecules whose tumor biological functions are also subjected to the determinative influences by p53 status. This evidence concerns the gene FOSB and neoplasm.